Targeted microwave ablation for prostate cancer (FOSTINE1b): a prospective ‘ablate‐and‐resect’ study
Objective To assess histopathological outcomes, as well as feasibility and safety of targeted microwave ablation (TMA) via the Trinity® system (KOELIS, La Tronche, France). Patients and methods Prospective, single‐institution, interventional Phase IIa study with an ‘ablate‐and‐resect’ design. In all...
Gespeichert in:
Veröffentlicht in: | BJU international 2024-08, Vol.134 (2), p.258-267 |
---|---|
Hauptverfasser: | , , , , , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 267 |
---|---|
container_issue | 2 |
container_start_page | 258 |
container_title | BJU international |
container_volume | 134 |
creator | Peltier, Alexandre Velthoven, Roland Baudewyns, Arthur Assenmacher, Grégoire Lemort, Marc Lefebvre, Yolene Sirtaine, Nicolas Diamand, Romain |
description | Objective
To assess histopathological outcomes, as well as feasibility and safety of targeted microwave ablation (TMA) via the Trinity® system (KOELIS, La Tronche, France).
Patients and methods
Prospective, single‐institution, interventional Phase IIa study with an ‘ablate‐and‐resect’ design. In all, 11 patients diagnosed with localised prostate cancer (PCa) underwent TMA via the Trinity system under conscious sedation in an outpatient setting using a single transrectal TATO® 18‐G antenna with different treatment regimens. Magnetic resonance imaging (MRI) and robot‐assisted radical prostatectomy (RARP) were conducted at 7 days and 1 month after TMA, respectively. Nine patients received RARP, and two patients chose to withdraw their consent following TMA. These men chose an active surveillance protocol upon confirmation of a low‐risk prostate cancer diagnosis. Functional outcomes and adverse events were evaluated at baseline and follow‐up visits using validated questionnaires. Prostate volumetry and confirmation of necrosis were carried out through MRI and whole‐mount histopathological examination.
Results
The TMA was successfully executed, and all patients were discharged on the same day. No severe adverse events (Common Terminology Criteria for Adverse Events Grade ≥3) were reported at the 7‐day and 1‐month follow‐up visits. Additionally, no declines were observed in urinary, sexual and ejaculation functional outcomes. T1‐weighted MRI revealed clear and well‐defined ablation zones. The RARP was executed without difficulty, particularly during the dissection of the posterior plane. As a result, no intraoperative complications were encountered. Histopathological assessment on surgical specimens confirmed the absence of viable cells, indicating complete necrosis of the ablative zone if a power intensity >10 W was used during TMA. Ablation zone volumetry revealed no notable distinctions between the three‐dimensional segmentation of the virtual ablation zone at TMA (median volume: 2 mL) and MRI (median volume: 1.923 mL). Conversely, a significant reduction was noted in the surgical specimen (median volume: 0.221 mL).
Conclusions
Targeted microwave ablation via the Trinity system for localised PCa treatment proves to be a secure and feasible procedure, with complete necrosis evidence within the ablation zone on surgical specimens. |
doi_str_mv | 10.1111/bju.16385 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3054841643</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>3081881682</sourcerecordid><originalsourceid>FETCH-LOGICAL-c3135-4e6324e699447b832142b8e4a4094206047a98aa88b4c491e324a555325ab64b3</originalsourceid><addsrcrecordid>eNp1kcFOGzEQhi1URCD0wAuglXoJhwR7Pet4ubURtFRROZBIva3GmwnaaLMb7F1QbnmEHtvXy5N0SKAHpPowtjzf_JqZX4gzJQeKz6VbtANltE0OxLECA31Q8ueHt7dMTUechLCQkj9MciQ62g4hBmWORTlB_0ANzaJlkfv6GZ8oQldiU9RVNK99tPJ1aLChKMcqJx_1bu7uJ7c_rpW7uIpwl15R3hRct9383pXSdvMLqxlHT4Fz282fKDTtbH0qDudYBvr4enfF9OZ6MvrWH999vR19HvdzrXTSBzI65pCmAENndawgdpYAeRSIpZEwxNQiWusgh1QR05gkiY4TdAac7oreXpe7e2wpNNmyCDmVJVZUtyHTMgHL44Nm9NM7dFG3vuLumLLKWmVszNTFnuIVheBpnq18sUS_zpTMXizI2IJsZwGz56-KrVvS7B_5tnMGLvfAc1HS-v9K2Zfv073kX-SKkZI</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3081881682</pqid></control><display><type>article</type><title>Targeted microwave ablation for prostate cancer (FOSTINE1b): a prospective ‘ablate‐and‐resect’ study</title><source>MEDLINE</source><source>Wiley Blackwell Single Titles</source><creator>Peltier, Alexandre ; Velthoven, Roland ; Baudewyns, Arthur ; Assenmacher, Grégoire ; Lemort, Marc ; Lefebvre, Yolene ; Sirtaine, Nicolas ; Diamand, Romain</creator><creatorcontrib>Peltier, Alexandre ; Velthoven, Roland ; Baudewyns, Arthur ; Assenmacher, Grégoire ; Lemort, Marc ; Lefebvre, Yolene ; Sirtaine, Nicolas ; Diamand, Romain</creatorcontrib><description>Objective
To assess histopathological outcomes, as well as feasibility and safety of targeted microwave ablation (TMA) via the Trinity® system (KOELIS, La Tronche, France).
Patients and methods
Prospective, single‐institution, interventional Phase IIa study with an ‘ablate‐and‐resect’ design. In all, 11 patients diagnosed with localised prostate cancer (PCa) underwent TMA via the Trinity system under conscious sedation in an outpatient setting using a single transrectal TATO® 18‐G antenna with different treatment regimens. Magnetic resonance imaging (MRI) and robot‐assisted radical prostatectomy (RARP) were conducted at 7 days and 1 month after TMA, respectively. Nine patients received RARP, and two patients chose to withdraw their consent following TMA. These men chose an active surveillance protocol upon confirmation of a low‐risk prostate cancer diagnosis. Functional outcomes and adverse events were evaluated at baseline and follow‐up visits using validated questionnaires. Prostate volumetry and confirmation of necrosis were carried out through MRI and whole‐mount histopathological examination.
Results
The TMA was successfully executed, and all patients were discharged on the same day. No severe adverse events (Common Terminology Criteria for Adverse Events Grade ≥3) were reported at the 7‐day and 1‐month follow‐up visits. Additionally, no declines were observed in urinary, sexual and ejaculation functional outcomes. T1‐weighted MRI revealed clear and well‐defined ablation zones. The RARP was executed without difficulty, particularly during the dissection of the posterior plane. As a result, no intraoperative complications were encountered. Histopathological assessment on surgical specimens confirmed the absence of viable cells, indicating complete necrosis of the ablative zone if a power intensity >10 W was used during TMA. Ablation zone volumetry revealed no notable distinctions between the three‐dimensional segmentation of the virtual ablation zone at TMA (median volume: 2 mL) and MRI (median volume: 1.923 mL). Conversely, a significant reduction was noted in the surgical specimen (median volume: 0.221 mL).
Conclusions
Targeted microwave ablation via the Trinity system for localised PCa treatment proves to be a secure and feasible procedure, with complete necrosis evidence within the ablation zone on surgical specimens.</description><identifier>ISSN: 1464-4096</identifier><identifier>ISSN: 1464-410X</identifier><identifier>EISSN: 1464-410X</identifier><identifier>DOI: 10.1111/bju.16385</identifier><identifier>PMID: 38742416</identifier><language>eng</language><publisher>England: Wiley Subscription Services, Inc</publisher><subject>Ablation ; Ablation Techniques - methods ; Adverse events ; Aged ; Ejaculation ; Feasibility Studies ; Focal therapy ; Functional magnetic resonance imaging ; Humans ; Image processing ; Magnetic Resonance Imaging ; Male ; microwave ; Microwave ablation ; Microwaves - therapeutic use ; Middle Aged ; Necrosis ; Prospective Studies ; Prostate cancer ; Prostatectomy ; Prostatectomy - methods ; Prostatic Neoplasms - pathology ; Prostatic Neoplasms - surgery ; radical prostatectomy ; Robotic Surgical Procedures ; Terminology ; Treatment Outcome</subject><ispartof>BJU international, 2024-08, Vol.134 (2), p.258-267</ispartof><rights>2024 BJU International.</rights><rights>Copyright © 2024 BJU International</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c3135-4e6324e699447b832142b8e4a4094206047a98aa88b4c491e324a555325ab64b3</cites><orcidid>0009-0008-0089-1030</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://onlinelibrary.wiley.com/doi/pdf/10.1111%2Fbju.16385$$EPDF$$P50$$Gwiley$$H</linktopdf><linktohtml>$$Uhttps://onlinelibrary.wiley.com/doi/full/10.1111%2Fbju.16385$$EHTML$$P50$$Gwiley$$H</linktohtml><link.rule.ids>314,776,780,1411,27901,27902,45550,45551</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/38742416$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Peltier, Alexandre</creatorcontrib><creatorcontrib>Velthoven, Roland</creatorcontrib><creatorcontrib>Baudewyns, Arthur</creatorcontrib><creatorcontrib>Assenmacher, Grégoire</creatorcontrib><creatorcontrib>Lemort, Marc</creatorcontrib><creatorcontrib>Lefebvre, Yolene</creatorcontrib><creatorcontrib>Sirtaine, Nicolas</creatorcontrib><creatorcontrib>Diamand, Romain</creatorcontrib><title>Targeted microwave ablation for prostate cancer (FOSTINE1b): a prospective ‘ablate‐and‐resect’ study</title><title>BJU international</title><addtitle>BJU Int</addtitle><description>Objective
To assess histopathological outcomes, as well as feasibility and safety of targeted microwave ablation (TMA) via the Trinity® system (KOELIS, La Tronche, France).
Patients and methods
Prospective, single‐institution, interventional Phase IIa study with an ‘ablate‐and‐resect’ design. In all, 11 patients diagnosed with localised prostate cancer (PCa) underwent TMA via the Trinity system under conscious sedation in an outpatient setting using a single transrectal TATO® 18‐G antenna with different treatment regimens. Magnetic resonance imaging (MRI) and robot‐assisted radical prostatectomy (RARP) were conducted at 7 days and 1 month after TMA, respectively. Nine patients received RARP, and two patients chose to withdraw their consent following TMA. These men chose an active surveillance protocol upon confirmation of a low‐risk prostate cancer diagnosis. Functional outcomes and adverse events were evaluated at baseline and follow‐up visits using validated questionnaires. Prostate volumetry and confirmation of necrosis were carried out through MRI and whole‐mount histopathological examination.
Results
The TMA was successfully executed, and all patients were discharged on the same day. No severe adverse events (Common Terminology Criteria for Adverse Events Grade ≥3) were reported at the 7‐day and 1‐month follow‐up visits. Additionally, no declines were observed in urinary, sexual and ejaculation functional outcomes. T1‐weighted MRI revealed clear and well‐defined ablation zones. The RARP was executed without difficulty, particularly during the dissection of the posterior plane. As a result, no intraoperative complications were encountered. Histopathological assessment on surgical specimens confirmed the absence of viable cells, indicating complete necrosis of the ablative zone if a power intensity >10 W was used during TMA. Ablation zone volumetry revealed no notable distinctions between the three‐dimensional segmentation of the virtual ablation zone at TMA (median volume: 2 mL) and MRI (median volume: 1.923 mL). Conversely, a significant reduction was noted in the surgical specimen (median volume: 0.221 mL).
Conclusions
Targeted microwave ablation via the Trinity system for localised PCa treatment proves to be a secure and feasible procedure, with complete necrosis evidence within the ablation zone on surgical specimens.</description><subject>Ablation</subject><subject>Ablation Techniques - methods</subject><subject>Adverse events</subject><subject>Aged</subject><subject>Ejaculation</subject><subject>Feasibility Studies</subject><subject>Focal therapy</subject><subject>Functional magnetic resonance imaging</subject><subject>Humans</subject><subject>Image processing</subject><subject>Magnetic Resonance Imaging</subject><subject>Male</subject><subject>microwave</subject><subject>Microwave ablation</subject><subject>Microwaves - therapeutic use</subject><subject>Middle Aged</subject><subject>Necrosis</subject><subject>Prospective Studies</subject><subject>Prostate cancer</subject><subject>Prostatectomy</subject><subject>Prostatectomy - methods</subject><subject>Prostatic Neoplasms - pathology</subject><subject>Prostatic Neoplasms - surgery</subject><subject>radical prostatectomy</subject><subject>Robotic Surgical Procedures</subject><subject>Terminology</subject><subject>Treatment Outcome</subject><issn>1464-4096</issn><issn>1464-410X</issn><issn>1464-410X</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp1kcFOGzEQhi1URCD0wAuglXoJhwR7Pet4ubURtFRROZBIva3GmwnaaLMb7F1QbnmEHtvXy5N0SKAHpPowtjzf_JqZX4gzJQeKz6VbtANltE0OxLECA31Q8ueHt7dMTUechLCQkj9MciQ62g4hBmWORTlB_0ANzaJlkfv6GZ8oQldiU9RVNK99tPJ1aLChKMcqJx_1bu7uJ7c_rpW7uIpwl15R3hRct9383pXSdvMLqxlHT4Fz282fKDTtbH0qDudYBvr4enfF9OZ6MvrWH999vR19HvdzrXTSBzI65pCmAENndawgdpYAeRSIpZEwxNQiWusgh1QR05gkiY4TdAac7oreXpe7e2wpNNmyCDmVJVZUtyHTMgHL44Nm9NM7dFG3vuLumLLKWmVszNTFnuIVheBpnq18sUS_zpTMXizI2IJsZwGz56-KrVvS7B_5tnMGLvfAc1HS-v9K2Zfv073kX-SKkZI</recordid><startdate>202408</startdate><enddate>202408</enddate><creator>Peltier, Alexandre</creator><creator>Velthoven, Roland</creator><creator>Baudewyns, Arthur</creator><creator>Assenmacher, Grégoire</creator><creator>Lemort, Marc</creator><creator>Lefebvre, Yolene</creator><creator>Sirtaine, Nicolas</creator><creator>Diamand, Romain</creator><general>Wiley Subscription Services, Inc</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7QP</scope><scope>7X8</scope><orcidid>https://orcid.org/0009-0008-0089-1030</orcidid></search><sort><creationdate>202408</creationdate><title>Targeted microwave ablation for prostate cancer (FOSTINE1b): a prospective ‘ablate‐and‐resect’ study</title><author>Peltier, Alexandre ; Velthoven, Roland ; Baudewyns, Arthur ; Assenmacher, Grégoire ; Lemort, Marc ; Lefebvre, Yolene ; Sirtaine, Nicolas ; Diamand, Romain</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c3135-4e6324e699447b832142b8e4a4094206047a98aa88b4c491e324a555325ab64b3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Ablation</topic><topic>Ablation Techniques - methods</topic><topic>Adverse events</topic><topic>Aged</topic><topic>Ejaculation</topic><topic>Feasibility Studies</topic><topic>Focal therapy</topic><topic>Functional magnetic resonance imaging</topic><topic>Humans</topic><topic>Image processing</topic><topic>Magnetic Resonance Imaging</topic><topic>Male</topic><topic>microwave</topic><topic>Microwave ablation</topic><topic>Microwaves - therapeutic use</topic><topic>Middle Aged</topic><topic>Necrosis</topic><topic>Prospective Studies</topic><topic>Prostate cancer</topic><topic>Prostatectomy</topic><topic>Prostatectomy - methods</topic><topic>Prostatic Neoplasms - pathology</topic><topic>Prostatic Neoplasms - surgery</topic><topic>radical prostatectomy</topic><topic>Robotic Surgical Procedures</topic><topic>Terminology</topic><topic>Treatment Outcome</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Peltier, Alexandre</creatorcontrib><creatorcontrib>Velthoven, Roland</creatorcontrib><creatorcontrib>Baudewyns, Arthur</creatorcontrib><creatorcontrib>Assenmacher, Grégoire</creatorcontrib><creatorcontrib>Lemort, Marc</creatorcontrib><creatorcontrib>Lefebvre, Yolene</creatorcontrib><creatorcontrib>Sirtaine, Nicolas</creatorcontrib><creatorcontrib>Diamand, Romain</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Calcium & Calcified Tissue Abstracts</collection><collection>MEDLINE - Academic</collection><jtitle>BJU international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Peltier, Alexandre</au><au>Velthoven, Roland</au><au>Baudewyns, Arthur</au><au>Assenmacher, Grégoire</au><au>Lemort, Marc</au><au>Lefebvre, Yolene</au><au>Sirtaine, Nicolas</au><au>Diamand, Romain</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Targeted microwave ablation for prostate cancer (FOSTINE1b): a prospective ‘ablate‐and‐resect’ study</atitle><jtitle>BJU international</jtitle><addtitle>BJU Int</addtitle><date>2024-08</date><risdate>2024</risdate><volume>134</volume><issue>2</issue><spage>258</spage><epage>267</epage><pages>258-267</pages><issn>1464-4096</issn><issn>1464-410X</issn><eissn>1464-410X</eissn><abstract>Objective
To assess histopathological outcomes, as well as feasibility and safety of targeted microwave ablation (TMA) via the Trinity® system (KOELIS, La Tronche, France).
Patients and methods
Prospective, single‐institution, interventional Phase IIa study with an ‘ablate‐and‐resect’ design. In all, 11 patients diagnosed with localised prostate cancer (PCa) underwent TMA via the Trinity system under conscious sedation in an outpatient setting using a single transrectal TATO® 18‐G antenna with different treatment regimens. Magnetic resonance imaging (MRI) and robot‐assisted radical prostatectomy (RARP) were conducted at 7 days and 1 month after TMA, respectively. Nine patients received RARP, and two patients chose to withdraw their consent following TMA. These men chose an active surveillance protocol upon confirmation of a low‐risk prostate cancer diagnosis. Functional outcomes and adverse events were evaluated at baseline and follow‐up visits using validated questionnaires. Prostate volumetry and confirmation of necrosis were carried out through MRI and whole‐mount histopathological examination.
Results
The TMA was successfully executed, and all patients were discharged on the same day. No severe adverse events (Common Terminology Criteria for Adverse Events Grade ≥3) were reported at the 7‐day and 1‐month follow‐up visits. Additionally, no declines were observed in urinary, sexual and ejaculation functional outcomes. T1‐weighted MRI revealed clear and well‐defined ablation zones. The RARP was executed without difficulty, particularly during the dissection of the posterior plane. As a result, no intraoperative complications were encountered. Histopathological assessment on surgical specimens confirmed the absence of viable cells, indicating complete necrosis of the ablative zone if a power intensity >10 W was used during TMA. Ablation zone volumetry revealed no notable distinctions between the three‐dimensional segmentation of the virtual ablation zone at TMA (median volume: 2 mL) and MRI (median volume: 1.923 mL). Conversely, a significant reduction was noted in the surgical specimen (median volume: 0.221 mL).
Conclusions
Targeted microwave ablation via the Trinity system for localised PCa treatment proves to be a secure and feasible procedure, with complete necrosis evidence within the ablation zone on surgical specimens.</abstract><cop>England</cop><pub>Wiley Subscription Services, Inc</pub><pmid>38742416</pmid><doi>10.1111/bju.16385</doi><tpages>10</tpages><orcidid>https://orcid.org/0009-0008-0089-1030</orcidid></addata></record> |
fulltext | fulltext |
identifier | ISSN: 1464-4096 |
ispartof | BJU international, 2024-08, Vol.134 (2), p.258-267 |
issn | 1464-4096 1464-410X 1464-410X |
language | eng |
recordid | cdi_proquest_miscellaneous_3054841643 |
source | MEDLINE; Wiley Blackwell Single Titles |
subjects | Ablation Ablation Techniques - methods Adverse events Aged Ejaculation Feasibility Studies Focal therapy Functional magnetic resonance imaging Humans Image processing Magnetic Resonance Imaging Male microwave Microwave ablation Microwaves - therapeutic use Middle Aged Necrosis Prospective Studies Prostate cancer Prostatectomy Prostatectomy - methods Prostatic Neoplasms - pathology Prostatic Neoplasms - surgery radical prostatectomy Robotic Surgical Procedures Terminology Treatment Outcome |
title | Targeted microwave ablation for prostate cancer (FOSTINE1b): a prospective ‘ablate‐and‐resect’ study |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-11T22%3A56%3A20IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Targeted%20microwave%20ablation%20for%20prostate%20cancer%20(FOSTINE1b):%20a%20prospective%20%E2%80%98ablate%E2%80%90and%E2%80%90resect%E2%80%99%20study&rft.jtitle=BJU%20international&rft.au=Peltier,%20Alexandre&rft.date=2024-08&rft.volume=134&rft.issue=2&rft.spage=258&rft.epage=267&rft.pages=258-267&rft.issn=1464-4096&rft.eissn=1464-410X&rft_id=info:doi/10.1111/bju.16385&rft_dat=%3Cproquest_cross%3E3081881682%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3081881682&rft_id=info:pmid/38742416&rfr_iscdi=true |